Resource table {#s0005}
==============

Name of stem cell lineKCL036InstitutionKing\'s College London, London UKDerivation teamNeli Kadeva, Victoria Wood, Glenda Cornwell, Stefano Codognotto, Emma StephensonContact person and emailDusko Ilic, email: <dusko.ilic@kcl.ac.uk>Date archived/stock dateNov 22, 2011Type of resourceBiological reagent: cell lineSub-typeHuman pluripotent stem cell lineOriginHuman embryoKey marker expressionPluripotent stem cell markers: NANOG, OCT4, TRA-1-60, TRA-1-81, alkaline phosphatase (AP) activityAuthenticationIdentity and purity of line confirmedLink to related literature (direct URL links and full references)1)Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy. 14 (1), 122--128.doi: 10.3109/14,653,249.2011.623692<http://www.ncbi.nlm.nih.gov/pubmed/22029654>2)Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D., 2012. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat. Protoc. 7 (7), 1366--1381.doi: 10.1038/nprot.2012.080<http://www.ncbi.nlm.nih.gov/pubmed/22722371>3)Jacquet, L., Neueder, A., Földes, G., Karagiannis, P., Hobbs, C., Jolinon, N., Mioulane, M., Sakai, T., Harding, S.E., Ilic, D., 2015. Three Huntington\'s Disease Specific Mutation-Carrying Human Embryonic Stem Cell Lines Have Stable Number of CAG Repeats upon In Vitro Differentiation into Cardiomyocytes. PLoS One. 10(5), e0126860.<http://www.ncbi.nlm.nih.gov/pubmed/25993131>Information in public databasesKCL036 is a National Institutes of Health (NIH) registered hESC line\
NIH Registration Number: 0241\
NIH Approval Number: NIHhESC-13-0241\
<http://grants.nih.gov/stem_cells/registry/current.htm?id=668>EthicsThe hESC line KCL036 is derived under license from the UK Human Fertilisation and Embryology Authority (research license numbers: R0075 and R0133) and also has local ethical approval (UK National Health Service Research Ethics Committee Reference: 06/Q0702/90).\
Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the NIH Belmont Report. No financial inducements are offered for donation.

Resource details {#s0010}
================

Consent signedJul 21, 2011Embryo thawedOct 23, 2011UK Stem Cell Bank Deposit ApprovalSep 13, 2012\
Reference: SCSC12-28SexMale 46, XYGradeResearchDisease status\
([Fig. 1](#f0005){ref-type="fig"})Mutation affecting one allele of the *HTT* gene encoding huntingtin (\~ 38 CAG repeats; 14 for the normal allele) associated with Huntington\'s disease (Ilic et al., 2015)Karyotype (aCGH)Decreased copy number at 2q37.3 (242,930,599--242,948,040) and at 3q25.1 (151,368,847--151,542,568). The imbalances are considered to be benign copy number variants. The chromosome 3 imbalance was not called by software.DNA fingerprintAllele sizes (in bp) of 17 microsatellite markers specific for chromosomes 13, 18 and 21 ([@bb0020])Viability testingPassPluripotent markers\
(immunostaining)\
([Fig. 2](#f0010){ref-type="fig"})NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity ([@bb0020])Three germ layers differentiation in vitro\
(immunostaining)\
([Fig. 3](#f0015){ref-type="fig"})Endoderm: AFP (α-fetoprotein); Ectoderm: TUBB3 (tubulin, β3 class III); Mesoderm: ACTA2 (actin, α2, smooth muscle) ([@bb0020])Three germ layer differentiation in vivo (teratomas)\
([Fig. 4](#f0020){ref-type="fig"})Endoderm: AFP, GATA4. Ectoderm: TUBB3, GFAP (glial fibrillary acidic protein). Mesoderm: DES (desmin), Alcian Blue and periodic acid--Schiff (PAS)-stained cartilage ([@bb0020])Targeted differentiation\
([Fig. 5](#f0025){ref-type="fig"})Cardiomyocytes: TNNT2 (cardiac troponin T) immunostainingSibling lines availableNone

We generated KCL036 research grade hESC line following protocols established previously ([@bb0005], [@bb0040], [@bb0025]). The expression of the pluripotency markers was tested after freeze/thaw cycle ([Fig. 2](#f0010){ref-type="fig"}; [@bb0020]). Differentiation potential into three germ layers was verified in vitro ([Fig. 3](#f0015){ref-type="fig"} and [Fig. 5](#f0025){ref-type="fig"}; [@bb0020]) and in vivo ([Fig. 4](#f0020){ref-type="fig"}; [@bb0020]).

Validation for sterility and specific and non-specific human pathogens confirmed that the cells in Master Bank were sterile, mycoplasma-free, and negative for human immunodeficiency virus 1 (HIV-1), Human T-lymphotropic virus type 1 (HTLV-1), hepatitis B and C (HBV and HCV), human herpes simplex virus HHV-4 (Epstein--Barr virus, EBV), and human cytomegalovirus (hCMV).

We also generated research grade of KCL036 line that is adapted to feeder-free conditions ([@bb0020]).

Materials and methods {#s0015}
=====================

Consenting process {#s0020}
------------------

We distribute patient information sheets (PIS) and consent forms to the in vitro fertilization (IVF) patients if they opted to donate to research embryos that were stored for 5 or 10 years. They mail signed consent back to us and that might be months after the PIS and consent were mailed to them. If in the meantime new versions of PIS/consent are implemented, we do not send these to the patients or ask them to re-sign; the whole process is done with the version that was given them initially. The PIS/consent documents (PGD-V.9) were created on Feb. 09, 2011. HFEA Code of Practice that was in effect at the time of document creation: Edition 8---R.2 (<http://www.hfea.gov.uk/2999.html>). The donor couple signed the consent on Jul. 21, 2011. HFEA Code of Practice that was in effect at the time of donor signature: Edition 8---R.3. HFEA Code of Practice Edition 8---R.2 was in effect: Apr. 07, 2010--Apr. 06, 2011. HFEA Code of Practice Edition 8---R.3 was in effect: Apr. 07, 2011--Oct. 01, 2011.

Embryo culture and micromanipulation {#s0025}
------------------------------------

Embryo culture and laser-assisted dissection of inner cell mass (ICM) were carried out as previously described in details ([@bb0005], [@bb0040]). The cellular area containing the ICM was then washed and transferred to plates containing mitotically inactivated human neonatal foreskin fibroblasts (HFF).

Cell culture {#s0030}
------------

ICM plated on mitotically inactivated HFF were cultured as described ([@bb0005], [@bb0040]). TE cells were removed mechanically from outgrowth ([@bb0015], [@bb0010]). hESC colonies were expanded and cryopreserved at the third passage.

Viability test {#s0035}
--------------

Straws with the earliest frozen passage (p.2--3) are thawed and new colonies are counted 3 days later. These colonies are then expanded up to passage 8, at which point cells were part frozen and part subjected to standard battery of tests (pluripotency markers, in vitro and in vivo differentiation capability, genetics, sterility, mycoplasma).

Pluripotency markers {#s0040}
--------------------

Pluripotency was assessed using two different techniques: enzymatic activity assay \[alkaline phosphatase (AP) assay\] and immunostaining as described ([@bb0005], [@bb0040]).

Differentiation {#s0045}
---------------

Spontaneous differentiation into three germ layers was assessed in vitro and in vivo ([@bb0020]) as described ([@bb0005], [@bb0040], [@bb0035]). Targeted differentiation in cardiomyocytes followed the protocols described earlier ([@bb0020], [@bb0030]).

Genotyping {#s0050}
----------

DNA was extracted from hESC cultures using a Chemagen DNA extraction robot according to the manufacturer\'s instructions. Amplification of polymorphic microsatellite markers was carried out as described ([@bb0005]). Allele sizes were recorded to give a unique fingerprint of each cell line.

Array comparative genomic hybridization (aCGH) {#s0055}
----------------------------------------------

aCGH was performed as described in details ([@bb0005]).

Special pathology {#s0060}
-----------------

The Doctors Laboratory London (UK) tested the line for HIV1, HepB, HepC, CMV, and EBV by PCR.

Author disclosure statement {#s0065}
===========================
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![Genetic pedigree tree. The couple undergoing IVF had 16 embryos in this particular cycle. Three embryos were normal, whereas those that carried the mutation in *HTT* were donated for research. We derived hESC lines from two of them.](gr1){#f0005}

![Expression of pluripotency markers. Pluripotency is confirmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Scale bar, 20 μm.](gr2){#f0010}

![Differentiation of three germ layers in vitro is confirmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm, and α-fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 25 μm.](gr3){#f0015}

![Differentiation of three germ layers in vivo. Teratomas were encapsulated and did not invade surrounding tissue. Sections are counterstained with hematoxylin and eosin and specific stains are brown (immunohistochemistry). Germ layer marker: DES for mesoderm, TUBB3 for ectoderm, and AFP for endoderm. Scale bars are 100 μm.](gr4){#f0020}

![TNNT2 (green) immunostaining on day 30 of cardiac differentiation. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.](gr5){#f0025}
